RxDoctor Payments DataLook up a doctor →

Gerald Calegan, MD

Neurology · Baton Rouge, LANPI 1902873516

Payments from drug & device makers

$399,897in general payments, 2019–2025

Across 2,531 payments — averaging $158.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$226K
  • Teva Pharmaceuticals USA, Inc.$79K
  • AbbVie$26K
  • Neurocrine Biosciences, Inc.$19K
  • Abbott$12K
  • Medtronic$12K
  • plus $27K from 51 others

What the payments were for

  • Consulting fees$23,4736%
  • Speaking & faculty fees$299,73475%
  • Travel & lodging$24,8846%
  • Food & beverage$51,26813%
  • Education$5370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Acadia Pharmaceuticals Inc437$226,074
Teva Pharmaceuticals USA, Inc.171$78,585
AbbVie(2 entities)405$25,914
Neurocrine Biosciences, Inc.235$18,778
Abbott89$12,044
Medtronic(2 entities)93$11,633
Amneal Pharmaceuticals LLC89$7,578
Amgen(2 entities)65$1,242
Biogen63$1,147
UCB, Inc.54$1,130
Novartis81$1,061
Adamas Pharmaceuticals, Inc.18$1,017
MDD US Operations, LLC32$1,009
Pfizer83$969
Sunovion Pharmaceuticals Inc.43$880
Acorda Therapeutics, Inc43$871
Lilly USA, LLC37$678
Sanofi36$663
Argenx US, Inc.29$656
AstraZeneca(2 entities)35$655
CSL Behring33$583
Lundbeck LLC32$581
Ipsen Biopharmaceuticals, Inc25$534
Grifols USA, LLC27$511
Eisai Inc.20$498
Kyowa Kirin, Inc.20$434
EMD Serono, Inc.24$392
Otsuka America Pharmaceutical, Inc.25$374
Neurelis, Inc.14$297
Merz Pharmaceuticals, LLC13$289
Genentech USA, Inc.14$273
GE HealthCare14$267
Takeda Pharmaceuticals U.S.A., Inc.12$249
Biohaven Pharmaceuticals, Inc.22$222
TG Therapeutics, Inc.13$219
Supernus Pharmaceuticals, Inc.13$208
Biohaven Pharmaceutical Holding Company Ltd.23$198
Saol Therapeutics Inc.1$193
Johnson & Johnson(2 entities)10$187
Revance Therapeutics, Inc.3$176
SK Life Science, Inc.8$146
Avanir Pharmaceuticals, Inc.8$124
Jazz Pharmaceuticals Inc.3$60
Impel Pharmaceuticals Inc.2$43
Boston Scientific1$40
Springworks Therapeutics, Inc.1$31
Vertical Pharmaceuticals, LLC2$31
Upsher-smith Laboratories LLC1$24
Alnylam Pharmaceuticals Inc.1$19
Averitas Pharma Inc.1$15
Zyla Life Sciences, Inc.1$14
Axsome Therapeutics, Inc.1$14
Azurity Pharmaceuticals, Inc.1$14
Currax Pharmaceuticals LLC1$14
Tanabe Pharma America, Inc.1$13
Sumitomo Pharma America, Inc.1$13
Insightec,inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$399,897 in reported general payments places this provider in the 95th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$366,193
Medicare patients
560
Services billed
37,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate459$2,248,196
RytaryCarbidopa/Levodopa410$449,908
AustedoDeutetrabenazine35$426,677
Austedo XrDeutetrabenazine32$366,168
IngrezzaValbenazine Tosylate38$311,550
XeominIncobotulinumtoxina65$74,523
BotoxOnabotulinumtoxina44$63,363
GocovriAmantadine Hcl15$51,468
Rasagiline Mesylate291$46,504
Carbidopa-LevodopaCarbidopa/Levodopa1,088$43,130
UbrelvyUbrogepant32$39,663
DysportAbobotulinumtoxina28$24,318
Entacapone134$16,183
Nurtec OdtRimegepant Sulfate15$15,996
XadagoSafinamide Mesylate13$14,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$226,074$2,248,196459 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$78,585$792,84467 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$7,578$450,909427 claims
Neurocrine Biosciences, Inc.Ingrezza$18,778$311,55038 claims
AbbVieBotox, Ubrelvy$25,914$103,02576 claims
MDD US Operations, LLCGocovri$1,009$51,46815 claims
Ipsen Biopharmaceuticals, IncDysport$534$24,31828 claims
PfizerNurtec Odt$969$15,99615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 neurology providers in Louisiana.

Other neurology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →